| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Vol. 50, Issue 1, 59-88, March 1998
Department of Cell Biology, PRAECIS Pharmaceuticals, Inc.,
Cambridge, Massachusetts
I. Introduction
II. The Complement System and Its Regulation
A. The Classical Pathway
B. The Alternative Pathway
C. The Membrane Attack Complex
III. Modified Native Complement Components That Block Complement
Activation
A. Soluble Complement Receptor Type 1
B. Soluble Complement-Receptor Type 1 Lacking Long Homologous
Repeat-A
C. Soluble Complement Receptor Type 1-Sialyl Lewisx
D. Complement Receptor Type 2
E. Soluble Decay Accelerating Factor
F. Soluble Membrane Cofactor Protein
G. Soluble CD59
H. Decay Accelerating Factor-CD59 Hybrid
I. Membrane Cofactor Protein-Decay Accelerating Factor Hybrid
J. C1 Inhibitor
K. C1q Receptor
IV. Complement-Inhibitory Antibodies
A. Anti-C5 Monoclonal Antibody
B. Anti-C5 Single Chain Fv
V. Synthetic Inhibitors of Complement Activation
A. Peptides and Analogs
B. Organic Molecules
VI. Naturally Occurring Compounds That Block Complement Activation
VII. Complement Inhibition in Xenotransplantation
VIII. Bispecific Antibodies for Immune Complex Removal
IX. Summary
Acknowledgments
References
This article has been cited by other articles:
|
|
 |
|
  R. M. Brodbeck, D. N. Cortright, A. P. Kieltyka, J. Yu, C. O. Baltazar, M. E. Buck, R. Meade, G. D. Maynard, A. Thurkauf, D.-S. Chien, et al. Identification and Characterization of NDT 9513727 [N,N-bis(1,3-Benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1H-imidazole-5-methanamine], a Novel, Orally Bioavailable C5a Receptor Inverse Agonist J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 898 - 909. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Girardi and N Mackman Tissue factor in antiphospholipid antibody-induced pregnancy loss: a pro-inflammatory molecule Lupus, October 1, 2008; 17(10): 931 - 936. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Katragadda, D. Morikis, and J. D. Lambris Thermodynamic Studies on the Interaction of the Third Complement Component and Its Inhibitor, Compstatin J. Biol. Chem., December 31, 2004; 279(53): 54987 - 54995. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. K. Ganesh, S. A. Smith, G. J. Kotwal, and K. H. M. Murthy Structure of vaccinia complement protein in complex with heparin and potential implications for complement regulation PNAS, June 15, 2004; 101(24): 8924 - 8929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yazdanbakhsh, S. Kang, D. Tamasauskas, D. Sung, and A. Scaradavou Complement receptor 1 inhibitors for prevention of immune-mediated red cell destruction: potential use in transfusion therapy Blood, June 15, 2003; 101(12): 5046 - 5052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Shields, J. Lai, R. Keck, L. Y. O'Connell, K. Hong, Y. G. Meng, S. H. A. Weikert, and L. G. Presta Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human Fcgamma RIII and Antibody-dependent Cellular Toxicity J. Biol. Chem., July 19, 2002; 277(30): 26733 - 26740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rehrig, S. D. Fleming, J. Anderson, J. M. Guthridge, J. Rakstang, C. E. McQueen, V. M. Holers, G. C. Tsokos, and T. Shea-Donohue Complement Inhibitor, Complement Receptor 1-Related Gene/Protein y-Ig Attenuates Intestinal Damage After the Onset of Mesenteric Ischemia/Reperfusion Injury in Mice J. Immunol., November 15, 2001; 167(10): 5921 - 5927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Abe, K. Shibata, H. Akatsu, N. Shimizu, N. Sakata, T. Katsuragi, and H. Okada Contribution of Anaphylatoxin C5a to Late Airway Responses After Repeated Exposure of Antigen to Allergic Rats J. Immunol., October 15, 2001; 167(8): 4651 - 4660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Larsen, R. R. Regal, and J. F. Regal Trimellitic Anhydride-Induced Allergic Response in the Guinea Pig Lung Involves Antibody-Dependent and -Independent Complement System Activation J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 284 - 292. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. J. Walport Complement- Second of Two Parts N. Engl. J. Med., April 12, 2001; 344(15): 1140 - 1144. [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. De Wolf and G. M. Brett Ligand-Binding Proteins: Their Potential for Application in Systems for Controlled Delivery and Uptake of Ligands Pharmacol. Rev., June 1, 2000; 52(2): 207 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Caliezi, W. A. Wuillemin, S. Zeerleder, M. Redondo, B. Eisele, and C. E. Hack C1-Esterase Inhibitor: An Anti-Inflammatory Agent and Its Potential Use in the Treatment of Diseases Other Than Hereditary Angioedema Pharmacol. Rev., March 1, 2000; 52(1): 91 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Heller, M. Hennecke, U. Baumann, J. E. Gessner, A. Meyer zu Vilsendorf, M. Baensch, F. Boulay, A. Kola, A. Klos, W. Bautsch, et al. Selection of a C5a Receptor Antagonist from Phage Libraries Attenuating the Inflammatory Response in Immune Complex Disease and Ischemia/Reperfusion Injury J. Immunol., July 15, 1999; 163(2): 985 - 994. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Blom, J. Webb, B. O. Villoutreix, and B. Dahlback A Cluster of Positively Charged Amino Acids in the C4BP alpha -Chain Is Crucial for C4b Binding and Factor I Cofactor Function J. Biol. Chem., July 2, 1999; 274(27): 19237 - 19245. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
 |
 |
 |
|
 |
 |
 |
